cyrilzakka/clinical-trials huggingface dataset:
Postoperative Infectious Complications Calculator for Elderly Patients

The investigators established a first-ever convenient scoring system for clinicians to assess the risk of Postoperative infectious complications (PICs) for elderly patients. Our scoring system can aid in the early detection of potential risks for postoperative infections. Higher-score patients were more likely to experience postoperative infections.

Background:

Postoperative infectious complications (PICs) are related to increased morbidity, mortality, and costs, especially in elderly patients. However, published prediction models of PICs are rarely based on elderly patients.

Objective:

The study wanted to identify practical and valuable variables that could be used to predict postoperative infections and establish a convenient scoring system for clinicians to assess the risk of such conditions in elderly patients.

Methods： Data from 2 population-based cohorts of elderly patients undergoing non-cardiac and non-neurology surgery were used to derive and validate multivariable logistic regression models. The risk prediction models were derived from 37230 patients hospitalized in the First Medical Center of the Chinese PLA General Hospital (January 2012 - August 2018). The risk prediction models were externally validated with data from a cohort of 10252 patients hospitalized in Henan Provincial People's Hospital (November 2014 to May 2022).

Eligibility Criteria:
Inclusion Criteria:

1. age ≥ 65 years and
2. patients undergoing surgery with anesthesia.

Exclusion Criteria:

1. patients undergoing neurosurgery or cardiac surgery,
2. preoperative infectious diseases, and
3. patients with ≥50% of data missing.
Chart Review of Patients Undergoing Ketamine Infusions

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.


Eligibility Criteria:
Inclusion Criteria:

1. Over the age of 18 years old. Patients over the age of 65 must receive additional approval to ensure safety.
2. Diagnosed with either MDD, BD, PTSD or OCD by a healthcare provider.
3. Experiencing an MDE as defined and operationalized in the DSM 5.0.
4. Individuals who may have comorbid psychiatric conditions, but the comorbid psychiatric condition can be neither the primary condition or the primary clinical concern.
5. Individuals reporting suicidal ideation will be included, as suicidal ideation is a symptom of MDE.
6. Individuals must have received at least 2 guideline concordant treatment trials with pharmacotherapeutic treatment options as suggested in the CANMAT MDD guidelines 2016, Florida Medicaid guidelines 2017, or the CANMAT ISBD guidelines for BD 2013.
7. Individuals who have received ECT or other neuromodulatory treatments will be eligible for ketamine infusion.

Exclusion Criteria:

1. Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months.
2. Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).
3. Individuals who are unable to consent to the treatment.
4. Individuals who are unable to adhere to the protocol in its totality (i.e., remain in the clinic post infusion for up to 2-3 hours for observation).
5. Individuals who are unable to identify a person to assure their safe transport home following ketamine infusion.
6. Individuals with symptomatic traumatic brain injury.
7. Uncontrolled medical disorders (i.e., uncontrolled and/or insufficiently treated hypertension, allergies to ketamine and/or previous intolerability of ketamine).
8. Pregnancy.
9. Medical contraindications to ketamine.
10. Patients that are over 275 lbs
Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)

Evaluation of Event free survival in patients with triple-negative thrombocytosis

Patients with non-reactive thrombocytosis, explored at least by bone marrow biopsy and NGS panel will be included. Clinical and biological characteristics as well as evolution will be recorded retrospectively.

Eligibility Criteria:
Inclusion Criteria:

* Patients with non reactive thrombocytosis for at least 6 months
* availability of bone marrow biopsy and NGS panel

Exclusion Criteria:

* Unable to consent
The Effect of Kinesio Taping Applied to Operating Room Nurses on Low Back Pain, Fatigue, and Sleep Quality

This study aims to determine the effects of kinesiology taping applied to operating room nurses on lower back pain, fatigue, and sleep quality. The research will be conducted using a randomized controlled experimental design with pre-test and post-test control groups. The universe of the study will consist of 100 operating room nurses working in a university hospital. The sample size has been calculated as a total of 84 nurses (Intervention group: 42; Control group: 42) based on power analysis calculations. The study will commence after obtaining the necessary permissions. Data collection will involve the use of the Descriptive Information Form, Visual Analog Scale, Quebec Back Pain Disability Scale, Visual Analogue Scale for Fatigue, and the Richards-Campbell Sleep Questionnaire. Participants who consent to the study will be administered the Descriptive Information Form, Visual Analog Scale, Quebec Back Pain Disability Scale, Visual Analogue Scale for Fatigue, and Richards-Campbell Sleep Questionnaire before the application of kinesiology tape. Subsequently, a physiotherapist from the research team will apply kinesiology tape to the paravertebral muscles using the muscle technique. As the literature suggests that the most suitable number of days for kinesiology tape application is four, participants will be instructed not to remove the tapes for four days. Additionally, participants will be informed that they can continue their daily activities and shower with the kinesiology tape on. The Visual Analog Scale will be applied to the participants at the end of the workday on the day of the kinesiology tape application and at the end of the workday for four days. At the end of the fourth day, all data collection tools will be applied. Seven days after the application, the scales will be filled out again by the nurses to determine if the effects of the kinesiology tape persist. Participants in the control group who agree to participate in the study will have data collected at the same time intervals as the intervention group participants using the same data collection tools. The Visual Analogue Scale will be administered to participants at the end of the day the data collection tools are filled out and at the end of the workday for four consecutive days. At the end of the fourth day, all data collection tools will be applied again. Seven days after the application, all scales will be refilled by the nurses..


Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the study
* Working in the operating room for at least one year

Exclusion Criteria:

* Presence of conditions that will prevent the application of kinesio tape (excessive hair in the area where it is applied, skin rash, urticaria, etc.)
* Necessity for continuous use of analgesics

Exclusion Criteria for the Study

* Desire to leave the study while the study is ongoing
* Allergic reaction or skin irritation to kinesio tape during the study
* Use of analgesics during the period when kinesio tape is applied
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to reduce the rest of the clonal plasma cell disease.


Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed amyloidosis

  * Diagnosed within the past 12 months
  * Clonal plasma cell disorder, as demonstrated by any of the following:

    * Presence of M-protein in serum and/or urine by immunofixation and/or serum free light chain assay
    * Clonal population of plasma cells in the bone marrow based on kappa/lambda staining of a marrow biopsy
* Negative genetic testing for hereditary forms of amyloidosis
* No amyloid-specific syndrome (e.g., carpal tunnel syndrome or skin purpura) as the only evidence of disease

  * Vascular amyloidosis only in a bone marrow biopsy specimen or in plasmacytoma is not indicative of systemic amyloidosis
* No advanced cardiac amyloidosis
* Must have symptomatic involvement of no more than 2 of the following visceral organ systems:

  * Kidneys
  * Liver/gastrointestinal
  * Peripheral/autonomic nervous system
  * Heart
* No persistent pleural effusions
* No clinically overt multiple myeloma with \> 30% plasma cells in the bone marrow or lytic bone lesions
* Able to undergo autologous stem cell transplantation

PATIENT CHARACTERISTICS:

* SWOG performance status 0-3
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Bilirubin \< 2.0 mg/dL
* Creatinine clearance \< 51 mL/min allowed
* LVEF \> 45% by echocardiogram
* No New York Heart Association class III-IV congestive heart failure
* No history of cardiac syncope
* No recurrent symptomatic arrhythmias
* No oxygen-dependent restrictive cardiomyopathy
* No myocardial infarction within the past 6 months
* Pulmonary diffusion capacity \> 50% predicted by pulmonary function testing
* No uncontrolled infection
* No other active malignancy, except for any of the following:

  * Adequately treated basal cell or squamous cell skin cancer
  * In situ cervical cancer
  * Adequately treated stage I cancer from which the patient is currently in complete remission
  * Any other cancer from which the patient has been disease-free for 5 years
* No hypersensitivity to bortezomib, boron, or mannitol
* No HIV positivity
* No serious medical or psychiatric illness that would preclude study compliance

PRIOR CONCURRENT THERAPY:

* At least 14 days since prior investigational drugs
* No prior therapy for monoclonal plasma disease
Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and their effect on blood glucose control, versus insulin glargine alone as active comparator in type 2 diabetes.

Due to the different mechanisms of action of the long-acting insulin analog insulin glargine and both a GLP-1 analog (exenatide) and a DPP-4-inhibitor (sitagliptin), it could be a promising approach to combine insulin glargine with either exenatide or sitagliptin for optimum control of fasting and postprandial blood glucose values. Thus, in the present study the influence of either exenatide or sitagliptin as a 4-week adjunctive therapy to a basal insulin (insulin glargine) was investigated versus insulin glargine alone as active comparator in subjects with type 2 diabetes. Preexisting metformin was continued, sulfonylureas, if any, were stopped. In particular, the effects on postprandial blood glucose excursion following ingestion of a standard breakfast, assessed after 4 weeks of treatment, the effects on mean daily blood glucose, on self-measured 7-point profiles, the percentage of subjects reaching ADA treatment goals (HbA1c \< 7.0%) at the end of treatment, on fasting lipid profile, on HOMA index, weight, hypoglycemic episodes and general safety were assessed. The study consisted of a screening visit, a 4-8 week (depending on pre-treatment) run-in period, a 4-week treatment period, and a follow-up visit. There were weekly visits at the site and twice weekly telephone contacts.

Eligibility Criteria:
Inclusion Criteria:

* male or female subjects aged between 35 and 70 years, inclusive
* type 2 diabetes with duration \>6 months and \<10 years
* for at least 3 months: treatment solely with a long- or intermediate-acting insulin formulation (insulin glargine, insulin detemir, or NPH insulin) with or without a stable dose of metformin or treatment solely with a stable dose of metformin or combination of stable doses of metformin plus sulfonylureas
* HbA1c \>=7.0% and \<=10.0%
* if treated with antihypertensive or lipid lowering agents, the treatment regimen had to be stable during 3 months prior to study start
* written informed consent

Exclusion Criteria:

* history or presence of cancer or any clinically relevant diseases
* chronic heart failure NYHA class III or IV, unstable angina pectoris or myocardial infarction within the previous 6 months
* recurrent hypoglycemia
* abnormal lab tests at screening (ALAT and/or ASAT \>=3 times ULN), creatinine \>1.6 mg/dL in males and \>1.4 mg/dL in females
* clinically relevant ECG findings at screening
* treatment with a rapid-acting insulin or with a mixed insulin formulation during the previous 3 months
* treatment with any other OHA than metformin or metformin plus sulfonylureas during the previous 3 months
* any systemic or topical treatment with drugs known to influence glucose metabolism
Correlation Between Respiratory Impairment and Phonemes Alteration in Dystrophinopathy Patients With Respiratory Failure

Communication is essential for patients quality of life because it impact on patients care quality. Neuromuscular diseases, caracterised by motor damages, hinder non-verbal communication of the patient. Therefore, speech must to be functional.

However, correlation between respiratory failure and voice quality is not very well known. The aim of the study is to search a link between respiratory failure and speech impairment in patients with neuromuscular diseases.


Eligibility Criteria:
Inclusion Criteria:

* Respiratory autonomy at least 1 hour per day
* Stable patient during the study
* Patient with education at least up to secondary school

Exclusion Criteria:

* Refusal to participate
* Inability to cooperate
* Tracheostomized patients
* Mechanic ventilation - dependant patients
* Respiratory autonomy lower than 1 hour per day
* Patients with hemodynamic instabillity
* Patient insured under the French social security system
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire

The purpose of this study is to define the endoscopic findings of minimal change that is significant to clinical significant reflux esophagitis. Through this, the investigators want to estimate the applicability of minimal change findings of reflux esophagitis to the clinic.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 20 years old patients who consent to revealing their medical information and be able to respond to questionnaires regarding the symptom.
* Patients who had shown the reflux esophageal minimal change in the endoscopic finding: the reflux esophagitis

Exclusion Criteria:

* Patients who had shown the mucosal break or barrett esophagus at gastric mucosal barrier or lower oesophagus in endoscopic findings
* Patient with a diagnosis of gastroesophageal reflux disease and who have received medication treatment
* Patient who had received H2-receptor antagonists, prostaglandin, PPI, NSAIDs or aspirin, high dose steroid and anticoagulants for at least 5 consecutive days in the 4-week period immediately preceding the diagnostic endoscopy
* Patients with a history of operation due to gastrointestinal disease, malignancy, alcoholism, pregnancy (in female), breast feeding (in female) or systemic disease
Text Message Study

The objectives of this double-blind, randomized, controlled study are to evaluate the efficacy of maintaining contact with low-back pain patients through text messaging and emailing, to decrease anxiety levels, pain, number of follow-up visits through text messaging and emailing, and to improve reporting of surgical site infection after spine surgery through text messaging and emailing. The outcomes that will be measured are anxiety, pain, follow-up visits and received phone calls, and reporting signs of surgical site infection. Participants will include Dr. Oren Gottfried's patients who underwent spine surgery at Duke Hospital or at Duke Raleigh Hospital. Patients will be approached after determination that the patient is going to undergo spinal surgery. All patients meeting inclusion criteria will be approached to participate irrespective of race or ethnicity. A total of 194 subjects will be recruited.


Eligibility Criteria:
Inclusion Criteria:

* Patients age greater than 18 years
* Patients who confirm they have an unlimited text message data plan and email capabilities on their mobile device
* Patients of Dr. Gottfried's underwent lumbar decompression or fusion surgery
* Patients with text message capabilities
* Patients who have an active email account

Exclusion Criteria:

* Patients who demonstrate an inability to fill out the pre-visit questionnaires
* Patients with a diagnosis of metastatic disease
* Patients with workers compensation or liability pending
* Patients who will require transfer to an acute rehabilitation facility following surgery
Honey Consumption, Oxidative Stress and Health

The aim of the present clinical study is to estimate the efficacy of a honey-based gel, derived from the wider area of Pindos in Greece, in regulating oxidative stress biomarkers and the physiological profile of healthy adults.

Introduction: Honey contains about 200 compounds such as sugars, proteins, vitamins, water, free amino acids, enzymes, minerals, and many phytochemicals. Due to its composition, enriched with many bioactive ingredients, several studies have established its antimicrobial, antiviral, anticancer, antidiabetic and antioxidant properties. This multilayer activity of honey has been proposed for the protection against pathologies interrelated with the cardiovascular, nervous, respiratory, and gastrointestinal system.

Purpose: This study aims to investigate the effects of a novel natural honey-based gel consumption on oxidative stress biomarkers, blood chemistry and physiological characteristics in healthy individuals.

Methodology: A total of 20 healthy men and women will participate in the study. Participants will give their informed consent after they will be informed about the purposes, procedures, risks and benefits associated with the study. Participants will consume 70 g/day of the honey-based gel, distributed in 2 equal doses (in the morning and evening) for 14 days. At baseline and post-intervention, volunteers will be assessed for their physiological profile and will provide a resting blood sample for the assessment of oxidative stress and blood chemistry biomarkers as well as their physiological profile. Participants will be asked to record their diet for 3 days prior to the study and they will be asked to follow the same dietary pattern for 3 days before the post-intervention assessments.

Eligibility Criteria:
Inclusion Criteria:

* Healthy Individuals aged 18-65 years
* Non-smokers

Exclusion Criteria:

* Musculoskeletal injury
* Dietary supplements
* Medication
* Allergy in bee pollen
Vastus Medialis Activation During McMurray's Test

This study will use electromyography to evaluate activation patterns of the vastus medialis and vastus lateralis muscles during the McMurray's knee examination test in different knee positions.

The McMurray test is commonly used to assess knee pathology. However, it is unclear which knee position during this test best isolates activity of the vastus medialis muscle. This study will measure vastus medialis and lateralis activation using surface electromyography in 30 healthy participants performing the McMurray test. Different knee flexion and rotation angles will be evaluated to determine which position optimally activates the vastus medialis. Results may enhance utilization of the McMurray test in rehabilitation programs targeting this muscle.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults aged 18-45 years
* No history of knee pathology

Exclusion Criteria:

* Contraindications to EMG
* Neurological or muscular disorders
Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)

The primary research question of this study is to determine whether measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD) can improve rates of treatment intensification and reduce levels of poorly controlled systolic blood pressure, LDL-c, and A1c.

Project Description: We propose a cluster randomized trial intervention involving eight or more medical facilities of Kaiser Permanente Northern California (KP) and more than 65,000 patients at high risk for CVD. At intervention facilities, patient-level information obtained from KP's electronic health record on the need for treatment intensification (for systolic blood pressure, LDL-c, and A1c) and on recent medication adherence are added to a population management database and fed back through software currently used by staff working with primary care providers. Staff at control facilities continue to use the same population management database and software but only receive information on risk factor levels and selected medications.

Specific Aims:

1. Evaluate the effectiveness of measurement and feedback of treatment intensification information in patients at high risk of CVD for improving rates of treatment intensification and for reducing levels of poorly controlled systolic blood pressure, LDL-c, and A1c.
2. Evaluate the impact of the intervention, compared with current practice, on total numbers of patient contacts, outpatient visits, and costs of care in relation to improvements in risk factor control.
3. Evaluate the effect of this innovation on physician and staff perceptions of the value (effectiveness and efficiency) of the population management program for high-risk patients.

Relevance: If this translational study shows that feedback of information on treatment intensification leads to higher rates of intensification and improved risk factor control, this finding will have shown a population-level use of health information technology for improving clinical quality and will also have validated treatment intensification as a metric of clinical quality.

Eligibility Criteria:
Inclusion Criteria:

Among the randomized medical facilities, we will study a population that is drawn from the PHASE registry and includes patients with at least one of the following:

* Diabetes, coronary artery disease; congestive heart failure; stroke/tia; peripheral artery disease; chronic kidney disease; hypertension; or hyperlipidemia
* PHASE patients must be in poor control for at least one CVD risk factor and meet study criteria for needing treatment intensification at some point during the 6-month period.

Exclusion Criteria:

* All patients eligible for the study will be included in the analyses
* There will be no exclusions based on clinical or other criteria.